Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Lowe`s Companies Inc (LOW) Price & Performance

Charles River Laboratories Intl. IncTrade
Lowe`s Companies IncTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Lowe`s Companies Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $231.21 (market cap $11.14B), while Lowe`s Companies Inc trades at $208.05 (market cap $116.45B). The key difference: Lowe`s Companies Inc is far larger — about 10.5× Charles River Laboratories Intl. Inc's market cap, and Lowe`s Companies Inc pays a 2.41% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.

CRLLOW
Market Cap
$11.14B$116.45B
Sector
HealthConsumer Cyclical
52-Week High
$233.60$287.39
52-Week Low
$145.57$206.62
Enterprise Value
$14.00B$158.20B
Dividend Yield
2.41%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.

Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.

Lowe`s Companies Inc

Lowe's (LOW) trades at $207.70, down 1.86% on the day, with a bearish technical signal from moving averages but oversold short-term RSI. The company maintains solid profitability with a 7.51% net margin and has beaten EPS estimates for three consecutive quarters. Revenue declined to $83.67B in 2025, though cash flow from operations improved to $9.63B. Recent news highlights Lowe's dividend growth strategy, with the quarterly payout rising to $1.25.

The outlook is mixed: strong analyst consensus (60.79% buy ratings) and a $260.88 price target suggest upside, but technical weakness and high debt levels pose risks. Earnings stability and dividend growth support long-term value, though housing market sensitivity and competitive pressures remain headwinds.

Returns comparison

Trailing returns across standard periods

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Lowe`s Companies Inc

Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.

Read more on LOW